Home About Contact Add Activities Provider Login

i3 Health

	Best Practices in Nursing Management of Chemotherapy-Induced Peripheral Neuropathy CIPN is a complication of cancer treatment that may lead to permanent nerve damage in severe cases. This online activity reviews causative agents, signs and symptoms, and supportive care interventions. 1.0 NCPD \| ILNA STATEMENT OF NEED Chemotherapy-induced peripheral neuropathy (CIPN) is a complication of cancer treatment that may impair quality of life and lead to treatment dose reductio... i3 Health
	Cracking the Code for Improved Patient Outcomes in Advanced Renal Cell Carcinoma STATEMENT OF NEED Renal cell carcinoma (RCC) comprises 2.4% of malignancies in adults worldwide (Makino et al, 2022). It is estimated that 79,000 new cases of kidney cancer were diagnosed in the US in 2022 (Siegel et al, 2022). RCC is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. Several new therapies have been a... i3 Health
	Diagnosis and Evidence-Based Management of T-Cell Lymphoma STATEMENT OF NEED T-cell lymphoma (TCL) is an uncommon subtype accounting for approximately 15% of all cases of non-Hodgkin lymphoma in the United States (LRF, 2022). Compared with its B-cell counterpart, TCL has a poor prognosis and is associated with a 5-year survival rate of less than 20%. The clinical and pathologic presentations of TCL are varied and often nonspecific, making diagnosis a... i3 Health
	Evolving Treatment Concepts and New Data in Advanced Prostate Cancer STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States. It is estimated that 268,490 new cases were diagnosed and that 34,500 people died of prostate cancer in 2022 (Siegel et al, 2022). Prostate cancer alone accounts for 27% of all cancer diagnoses in men (ACS, 2022). To optimize outcomes for patients with prostate cancer, it is critical for health... i3 Health
	Key Considerations in Managing Atopic Dermatitis in Black Patients Statement of Need Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong... i3 Health
	Management of Cancer Pain: Current Guidelines STATEMENT OF NEED Patients with cancer often suffer from a range of symptoms that negatively impact their quality of life. Among the most significant of these symptoms is pain, which can be caused by surgery, radiation, chemotherapy, targeted therapy, diagnostic procedures, and/or supportive care measures. Between 20% and 50% of patients with cancer experience pain, including moderate-to-seve... i3 Health
	Managing Symptom Burden and Optimizing Treatment Outcomes in Myelofibrosis Learn more about myelofibrosis risk factors, novel therapies to slow disease progression and reduce symptoms, and strategies to maintain quality of life in this comprehensive activity presented by John Mascarenhas, MD, Professor of Medicine at Mount Sinai Icahn School of Medicine. Start the activity now! STATEMENT OF NEED Myelofibrosis is a rare myeloproliferative neoplasm characterized by... i3 Health
	New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease STATEMENT OF NEED Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the fi... i3 Health
	New Perspectives in the Management of Marginal Zone Lymphoma STATEMENT OF NEED Marginal zone lymphoma (MZL) comprises approximately 7% of all mature non-Hodgkin lymphomas (NHLs) (Cerhan & Haberman, 2021). According to the World Health Organization classification, there are three subtypes: extranodal MZL, also referred to as mucosa-associated lymphatic tissue (MALT) lymphoma; splenic MZL, which originates from memory B lymphocytes located in the mar... i3 Health
	Novel Breast Cancer Therapies: Antibody-Drug Conjugates STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drug... i3 Health
	Novel Breast Cancer Therapies: CDK4/6 Inhibitors STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors a... i3 Health
	Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-posit... i3 Health
	Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy appr... i3 Health
	Novel Breast Cancer Therapies: Monoclonal Antibodies STATEMENT OF NEED Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling do... i3 Health
	Novel Breast Cancer Therapies: PARP Inhibitors STATEMENT OF NEED Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected dele... i3 Health
	Novel Breast Cancer Therapies: PI3K Inhibitors STATEMENT OF NEED Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha... i3 Health
	Nursing Management of Bone Health in Patients with Cancer Once it has metastasized to the skeletal system, cancer often negatively affects bone health, leading to pain, fractures, hypercalcemia, and nerve compression. This online activity reviews interventions to reduce morbodity and mortality of bone complications in patients with cancer. STATEMENT OF NEED Advanced-stage cancers, including lung, breast, prostate, and multiple myeloma, can have ... i3 Health
	Nursing Management of Cancer Treatment-Induced Cardiotoxicity Studies have shown that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often result in death. This activity reviews recent advances in the management of cancer teatment-induced cardiotoxicity. STATEMENT OF NEED Several studies reveal that certain cancer therapies adversely affect the heart and lead to various types of injuries, which often ... i3 Health
	Nursing Management of Oral Mucositis Oral mucositis is considered one of the most debilitating side effects of cancer therapy. This online activity reviews pathobiology, risk factors, clinical assessment, and supportive care interventions. STATEMENT OF NEED Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). ... i3 Health
	Nursing Management of Tumor Lysis Syndrome STATEMENT OF NEED Tumor lysis syndrome (TLS) is an oncological emergency that occurs when massive tumor lysis causes the rapid release of intracellular components into the bloodstream. Electrolyte imbalances characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia may be severe enough to cause acute renal failure, cardiac arrhythmias, seizures, and even death. Current... i3 Health
	Nursing Management of Venous Thromboembolism in Ambulatory Patients With Cancer VTE is a common and potentially life-threatening complication in patients with cancer. This online activity reviews VTE pathophysiology, risk assessment, and supportive care interventions for ambulatory cancer patients. Venous thromboembolism (VTE) is a common and potentially life-threatening complication in patients with cancer. There are two main types of VTE: deep vein thrombosis (DVT) and... i3 Health
	Nursing Management of Venous Thromboembolism in Hospitalized Patients With Cancer VTE is a life-threatening complication in hospitalized patients with cancer, and is associated with a 2- to 6-fold increase in likelihood of death. This online activity reviews signs and symptoms, risk assessment, and supportive care interventions. STATEMENT OF NEED Venous thromboembolism (VTE), which consists primarily of deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-t... i3 Health
	Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma STATEMENT OF NEED Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerg... i3 Health
	Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in... i3 Health
	Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States. An estimated 268,490 new cases are diagnosed annually, and 34,500 people die of the disease (ACS, 2022). Typically, androgen deprivation therapy (ADT) is administered for progressive disease. However, castration resistance or unresponsiveness to ADT or antiandrogens frequently develop over time... i3 Health
	Podcast: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical... i3 Health
	Podcast: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer This expert-led episode of Oncology Data Advisor TM, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive ... i3 Health
	Podcast: Key Considerations in Managing Atopic Dermatitis in Black Patients Statement of Need Atopic dermatitis (AD), a severe form of eczema and intense pruritus, is associated with a substantial and multifaceted patient-reported burden that encompasses sleep disturbances, anxiety, depression, reduced function/productivity, and impaired quality of life. The incidence of AD is high, estimated to be approximately 15%-20% in children and 1%-3% in adults worldwide (Yong... i3 Health
	Podcast: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing... i3 Health
	Podcast: New Opportunities for Improved Patient Outcomes in Graft-Versus-Host-Disease STATEMENT OF NEED Graft-versus-host disease (GHVD) is a common complication of allogeneic hematopoietic stem cell transplant (HSCT) and a major contributor to morbidity and mortality (DeFilipp et al, 2021; Malard et al, 2020). Acute GVHD occurs within 100 days of transplant and typically targets the skin, gastrointestinal tract, and liver (LLS, 2022). Chronic GVHD often presents within the fi... i3 Health
	Podcast: Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in... i3 Health
	Prevention of Medical Errors in Nursing Practice Medical errors are among the most common health-threatening mistakes that affect patient care. This online activity reviews the categories of medication errors, at-risk patient populations, and best practices in error analysis and reporting. STATEMENT OF NEED Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 dea... i3 Health
	Video Viewpoint Strategy Session: Emerging Checkpoint Inhibitor–Based Strategies for Advanced Endometrial Cancer Gain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of O... i3 Health
	Video Viewpoint Strategy Session: Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer This expert-led discussion, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse ev... i3 Health
	Video Viewpoint Strategy Session: New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Discover recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. This activity is presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing... i3 Health

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map